Zentalis Pharmaceuticals (ZNTL)
(Real Time Quote from BATS)
$12.60 USD
+0.08 (0.64%)
Updated May 10, 2024 09:45 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZNTL 12.60 +0.08(0.64%)
Will ZNTL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?
Other News for ZNTL
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib